journal article·2025-02-05

A One-Step Plasma Assisted Synthesis of Gold Nanoparticles and Simultaneous Linker-Free Conjugation with Nestin: An In Vitro Study of Cellular Toxicity

Melika Sanavandi, Kimia Aalikhani, Mojtaba Shafiee, Hodjatallah Rabbani, Ghazaleh Fazli, Niloufar Sadeghi, Babak Shokri

Nano Letters· Volume 25· Issue 5
Publisher page

Abstract

We present a method for conjugating antigens to gold nanoparticles (GNPs) during their synthesis via gas plasma, eliminating the need for chemical linkers and significantly speeding up the process (taking only 15 min). This fast, linker-free method produces biocompatible and stable GNPs, with potential for immunotherapy applications, such as antigen and antibody conjugation and drug delivery. We demonstrate the conjugation of the antigen Nestin (NES), a tumor marker, to GNPs using two approaches. The first method involves synthesizing GNPs with citrate, followed by NES conjugation via plasma. The second method synthesizes and conjugates GNPs to NES simultaneously using plasma treatment. Conjugation was confirmed by Enzyme-Linked Immunosorbent Assay, Zeta-sizer, UV–vis spectroscopy, and Transmission Electron Microscopy . In addition, the toxicity of the prepared samples was investigated in vitro using peripheral blood mononuclear cells (PBMCs) and flow cytometry, which proved the nontoxicity of the samples.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Gold and Silver Nanoparticles Synthesis and Applications · Nanoparticle-Based Drug Delivery · Nanoparticles: synthesis and applications

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Physics

Shahid Beheshti University

Laser and Plasma Research Institute

Institute of Medical Biotechnology

National Institute of Genetic Engineering & Biotechnology (NIGEB)

Monoclonal Antibody Research Center, Avicenna Research Institute, ACECR

Funding

PADZA PADTAN PAJHOOH

References (65)

Show source-provided references
1. 10.1038/s41467-023-42509-710.1038/s41467-023-42509-7 ↗
2. 10.1038/s41467-023-40851-410.1038/s41467-023-40851-4 ↗
3. 10.1016/j.matpr.2020.12.82610.1016/j.matpr.2020.12.826 ↗
4. 10.1016/j.jksus.2021.10156010.1016/j.jksus.2021.101560 ↗
5. 10.1021/acs.chemmater.5b0440610.1021/acs.chemmater.5b04406 ↗
6. 10.14356/kona.202001110.14356/kona.2020011 ↗
7. 10.1016/j.arabjc.2022.10439510.1016/j.arabjc.2022.104395 ↗
8. 10.1039/D3NA00007A10.1039/D3NA00007A ↗
9. 10.1007/s10876-020-01955-910.1007/s10876-020-01955-9 ↗
10. 10.1016/j.pdpdt.2019.01.02710.1016/j.pdpdt.2019.01.027 ↗
11. 10.3390/molecules2809393110.3390/molecules28093931 ↗
12. 10.1039/D2CP03866H10.1039/D2CP03866H ↗
13. 10.1016/j.jrras.2022.10049010.1016/j.jrras.2022.100490 ↗
14. 10.1016/j.microc.2023.10869810.1016/j.microc.2023.108698 ↗
15. 10.1039/D2NA00600F10.1039/D2NA00600F ↗
16. 10.1007/s11094-023-02847-810.1007/s11094-023-02847-8 ↗
17. 10.3389/fnano.2023.113278310.3389/fnano.2023.1132783 ↗
18. 10.1016/j.nano.2022.10260910.1016/j.nano.2022.102609 ↗
19. 10.1016/j.ijbiomac.2023.12718410.1016/j.ijbiomac.2023.127184 ↗
20. 10.1021/acs.molpharmaceut.2c0015010.1021/acs.molpharmaceut.2c00150 ↗
21. 10.1080/03639045.2017.133908210.1080/03639045.2017.1339082 ↗
22. 10.1186/s12931-023-02473-810.1186/s12931-023-02473-8 ↗
23. 10.1007/s00018-018-2794-z10.1007/s00018-018-2794-z ↗
24. 10.1007/s00018-004-4144-610.1007/s00018-004-4144-6 ↗
25. 10.1186/1471-213X-7-8910.1186/1471-213X-7-89 ↗
26. 10.14712/18059694.2017.2010.14712/18059694.2017.20 ↗
27. 10.3748/wjg.v19.i1.4210.3748/wjg.v19.i1.42 ↗
28. 10.3748/wjg.v17.i4.40910.3748/wjg.v17.i4.409 ↗
29. 10.1177/1179554921103825610.1177/11795549211038256 ↗
30. 10.1177/1066896922112579210.1177/10668969221125792 ↗
31. Zhang X. · Cancer Cell International · 2020 · 20 · 16910.1186/s12935-020-01252-5 ↗
32. 10.1016/j.canlet.2019.03.03910.1016/j.canlet.2019.03.039 ↗
33. 10.1016/j.biocel.2019.01.00210.1016/j.biocel.2019.01.002 ↗
34. 10.5152/tjg.2023.2248510.5152/tjg.2023.22485 ↗
35. 10.5603/GP.a2017.002310.5603/GP.a2017.0023 ↗
36. 10.1016/j.jhep.2022.07.01910.1016/j.jhep.2022.07.019 ↗
37. 10.1111/his.1396610.1111/his.13966 ↗
38. 10.3389/fonc.2020.0136710.3389/fonc.2020.01367 ↗
39. Miloudi S. · Molecular Vision · 2022 · 28 · 280
40. Hermanson G. T. · 2013
41. 10.3390/ijms2021524310.3390/ijms20215243 ↗
42. 10.1002/advs.20180067210.1002/advs.201800672 ↗
43. Donaghy H. · 2016
44. 10.1016/j.progpolymsci.2020.10124110.1016/j.progpolymsci.2020.101241 ↗
45. 10.1117/1.JBO.25.5.05600410.1117/1.JBO.25.5.056004 ↗
46. 10.1021/acs.bioconjchem.5b0026410.1021/acs.bioconjchem.5b00264 ↗
47. 10.1038/nchembio.72010.1038/nchembio.720 ↗
48. 10.4155/bio-2018-025910.4155/bio-2018-0259 ↗
49. 10.3390/jfb1408040710.3390/jfb14080407 ↗
50. 10.1186/1556-276X-8-7210.1186/1556-276X-8-72 ↗
51. 10.1021/bc700227z10.1021/bc700227z ↗
52. 10.3390/ma1213210710.3390/ma12132107 ↗
53. 10.1186/s12951-018-0362-110.1186/s12951-018-0362-1 ↗
54. 10.4155/bio-2019-027110.4155/bio-2019-0271 ↗
55. 10.1016/j.jconrel.2013.05.02510.1016/j.jconrel.2013.05.025 ↗
56. 10.3390/antib703003010.3390/antib7030030 ↗
57. 10.1109/TCSI.2015.249578010.1109/TCSI.2015.2495780 ↗
58. 10.1111/j.1398-9995.1998.tb04975.x10.1111/j.1398-9995.1998.tb04975.x ↗
59. Hadavi R. · Avicenna Journal of Medical Biotechnology · 2010 · 2 · 69
60. 10.1021/acsomega.8b0026510.1021/acsomega.8b00265 ↗
61. 10.1002/ppap.20140012710.1002/ppap.201400127 ↗
62. 10.1063/5.002604710.1063/5.0026047 ↗
63. 10.1021/acsnano.0c0843110.1021/acsnano.0c08431 ↗
64. 10.1038/s41598-018-22976-510.1038/s41598-018-22976-5 ↗
65. 10.1039/D0GC01348J10.1039/D0GC01348J ↗